High expression of EZH2 as a marker for the differential diagnosis of malignant and benign myogenic tumors

Zhang, Ning; Zeng, Zhi; Li, Shaobo; Wang, Fei; Huang, Peng

doi:10.1038/s41598-018-30648-7

Cited by 8 publications

(10 citation statements)

References 31 publications

(23 reference statements)

Supporting

Mentioning

Contrasting

Order By: Relevance

“…The subgroup analysis in those previously published studies showed that high EZH2 expression remained as a highly sensitive and specific marker in distinguishing lower grade malignancies from benign neoplasms (e.g., well‐differentiated leiomyosarcoma vs. leiomyoma) 6,7 . Similar to the findings of the previous studies, the current study has shown that EZH2 might be a promising marker to distinguish fibromatosis‐like MBC from the benign spindle cell neoplasms of the breast such as fibromatosis, therefore, larger studies should confirm this finding.…”

Section: Discussionsupporting

confidence: 88%

“…The main significance of EZH2 overexpression in cancer, including breast cancer, is that high EZH2 expression is usually associated with worse pathologic features, invasion, metastasis and poor clinical outcome 3,9–13 . Apart from its clinical‐related significance, the diagnostic utility of EZH2 expression was previously evaluated to differentiate malignant tumors from their benign counterparts in many organs such as cervix, mesothelium, myometrium and shown to be a promising diagnostic marker 6,7,14,14,15 . As spindle cell lesions of the breast are one of the challenging diagnostic areas for pathologists, we explored the significance of EZH2 expression in distinguishing benign and malignant spindle cell tumors of the breast.…”

Section: Discussionmentioning

confidence: 99%

“…Recently, high EZH2 expression was shown to be a promising marker in differentiating the benign and malignant uterine spindle cell smooth muscle tumors, as well as benign and malignant mesothelial proliferations 6,7 . In this study, we explored the significance of EZH2 expression in various spindle cell lesions of the breast to be potentially used for diagnostic and treatment purposes.…”

Section: Introductionmentioning

confidence: 99%

See 2 more Smart Citations

The significance of enhancer of zeste homolog 2 (EZH2) expression in spindle cell lesions of the breast

Genco

Hackman

Morrar

et al. 2021

Pathology International

View full text Add to dashboard Cite

Spindle cell lesions of the breast are rare entities and pose a diagnostic challenge for pathologists due to overlapping morphologic and immunohistochemical features. We evaluated EZH2 expression in various benign (fibromatosis (n = 8), myofibroblastoma (n = 7), neurofibroma (n = 1), nodular fasciitis (n = 5), benign phyllodes tumor (n = 18)) and malignant (malignant phyllodes tumor (n = 8), metaplastic breast carcinoma (n = 16) and angiosarcoma (n = 8)) spindle cell lesions as a potential diagnostic and therapeutic marker. The EZH2 expression was evaluated semi‐quantitatively to categorize the cases as ‘low’ and ‘high’ expression. All benign lesions showed low EZH2 expression, whereas high EZH2 expression was observed in the majority (28/32; 88%) of malignant lesions. The study results suggest that EZH2 may be used both as an additional diagnostic tool to reach an accurate diagnosis of the spindle cell lesions of the breast and as a therapeutic target for the malignant lesions.

show abstract

Section: Discussionsupporting

confidence: 88%

Section: Discussionmentioning

confidence: 99%

Section: Introductionmentioning

confidence: 99%

See 1 more Smart Citation

The significance of enhancer of zeste homolog 2 (EZH2) expression in spindle cell lesions of the breast

Genco

Hackman

Morrar

et al. 2021

Pathology International

View full text Add to dashboard Cite

show abstract

“…Rather, EZH2 is overexpressed in many STS in comparison to normal tissue, which may be attributed to the cell of origin of these tumours. STS are thought to be derived from mesenchymal stem cells, where the balance of EZH2 expression along with other histone modifying enzymes is thought to control the differentiation lineage process [16][17][18][19] . The reason why overexpression of wildtype EZH2 leads to associated poor outcomes can primarily be understood in terms of the normal function of EZH2.…”

Section: Role Of Ezh2 In Stsmentioning

confidence: 99%

Targeting EZH2 for the treatment of soft tissue sarcomas

Karolak¹,

Tracy²,

Shipley³

et al. 2021

JCMT

View full text Add to dashboard Cite

Soft tissue sarcomas (STS) are a heterogenous group of rare malignancies of mesenchymal origin, affecting both children and adults. The majority of STS have a poor prognosis and advanced stage at the time of diagnosis. Standard treatments for STS largely constitute tumour resection with chemotherapy and/or radiotherapy, and there has been little significant advancement in the application of novel therapies for treatment of these tumours. The current multimodal approach to therapy often leads to long-term side effects, and for some patients, resistance to cytotoxic agents is associated with local recurrence and/or metastasis. There is, therefore, a need for novel therapeutic strategies for the treatment of STS. Recent advances in epigenetics have implicated the histone methyltransferase, EZH2, in the development and progression of diseases such as breast cancer, lymphoma and more recently STS. Here we will review the current literature for EZH2 in STS, including high expression of EZH2 in STS and correlation of this with specific features of malignancy (metastasis, histological grade, and prognosis). The effects of targeting EZH2 using RNA interference and small molecule inhibitors will also be reviewed and the potential for the use of EZH2 inhibition in therapeutic strategies for STS patients will be discussed.

show abstract

“…The abundance of EZH2 protein in RMS and its association with poor prognosis, increased metastasis and lymph node involvement make EZH2 an interesting therapeutic target [ 24 , 25 , 26 ]. Different approaches to affect EZH2 have been investigated [ 27 ].…”

Section: Introductionmentioning

confidence: 99%

The Effect of Direct and Indirect EZH2 Inhibition in Rhabdomyosarcoma Cell Lines

Schmidt

Behrendt

Eybe

et al. 2021

Cancers

View full text Add to dashboard Cite

Enhancer of Zeste homolog 2 (EZH2) is involved in epigenetic regulation of gene transcription by catalyzing trimethylation of histone 3 at lysine 27. In rhabdomyosarcoma (RMS), increased EZH2 protein levels are associated with poor prognosis and increased metastatic potential, suggesting EZH2 as a therapeutic target. The inhibition of EZH2 can be achieved by direct inhibition which targets only the enzyme activity or by indirect inhibition which also affects activities of other methyltransferases and reduces EZH2 protein abundance. We assessed the direct inhibition of EZH2 by EPZ005687 and the indirect inhibition by 3-deazaneplanocin (DZNep) and adenosine dialdehyde (AdOx) in the embryonal RD and the alveolar RH30 RMS cell line. EPZ005687 was more effective in reducing the cell viability and colony formation, in promoting apoptosis induction, and in arresting cells in the G1 phase of the cell cycle than the indirect inhibitors. DZNep was more effective in decreasing spheroid viability and size in both cell lines than EPZ005687 and AdOx. Both types of inhibitors reduced cell migration of RH30 cells but not of RD cells. The results show that direct and indirect inhibition of EZH2 affect cellular functions differently. The alveolar cell line RH30 is more sensitive to epigenetic intervention than the embryonal cell line RD.

show abstract

High expression of EZH2 as a marker for the differential diagnosis of malignant and benign myogenic tumors

Cited by 8 publications

References 31 publications

The significance of enhancer of zeste homolog 2 (EZH2) expression in spindle cell lesions of the breast

The significance of enhancer of zeste homolog 2 (EZH2) expression in spindle cell lesions of the breast

Targeting EZH2 for the treatment of soft tissue sarcomas

The Effect of Direct and Indirect EZH2 Inhibition in Rhabdomyosarcoma Cell Lines

Contact Info

Product

Resources

About